newsfilter
← Latest News
PR Newswire·

Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2023 Financial Results

-- THE-630 initial dose escalation data to be presented at investor event on May 25, 2023, with additional dose escalation data expected in Q4 2023 -- -- IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4